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AbstrAct
An age-related decline in cytolytic activity has been described in CD8+ T cells and 
we have previously shown that the poor CD8+ effector T cell responses to influenza A/
H3N2 challenge result from a decline in the proportion and function of these cytolytic 
T lymphocytes (CTL). Here, we describe that addition of exogenous cytokines to 
influenza-stimulated PBMC from both aged mice and humans, enhances the generation 
of influenza specific CD8 CTL by increasing their proliferation and survival. Our data 
show that the addition of IL-2 and IL-6 to splenocytes from mice previously infected 
with influenza virus restores the aged CD8+ T cell response to that observed in young 
mice. In humans, IL-2 plus IL-6 also reduces the proportion of apoptotic effector CD8+ 
T cells to levels resembling those of younger adults. In HLA-A2+ donors, MHC Class 
I tetramer staining showed that adding both exogenous IL-2 and IL-6 resulted in 
greater differentiation into influenza-specific effector CD8+ T cells. Since this effect of 
IL-2/IL-6 supplementation can be reproduced with the addition of Toll-like receptor 
agonists, it may be possible to exploit this mechanism and design new vaccines to 
improve the CD8 T cell response to influenza vaccination in older adults. 
IntroductIon
The current split virus influenza vaccines are 
designed to stimulate protective antibody responses but 
they often fail to provide protection in older adults. As 
a result, hospitalization and death rates due to influenza 
have continued to increase over the last two decades in 
spite of widespread influenza vaccination programs [1-3], 
providing an impetus for the discovery of more effective 
influenza vaccines.
A multitude of changes in the immune system occur 
with aging, but the specific mechanisms that increase risk 
for influenza illness and limit the protective effects of 
vaccination in older adults remain poorly understood. Age-
related changes in T cell responses are associated with a 
decline in antibody responses to influenza vaccination 
[4, 5]. Nevertheless, the nature and specific mechanisms 
involved in declines in vaccine efficacy in old age remain 
unclear. We have shown that older people who develop 
influenza illness have low levels of the cytolytic mediator, 
granzyme B (GrB), and a lower ratio of IFNγ:IL-10 
released from peripheral blood mononuclear cells (PBMC) 
following challenge with live influenza virus [6-8]. These 
results suggest a shift away from a more effective T helper 
type 1 (Th1) and related cytolytic response, toward a less 
effective response to influenza challenge with aging [9]. 
In parallel studies conducted in a mouse model of 
aging, we have previously demonstrated that IL-2 [10, 11] 
and pro-inflammatory cytokines such as IL-6 [12, 13], can 
restore the generation, memory and responses of CD4+ 
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effector T cells from naïve CD4+ T cells to those seen in 
younger animals. Moreover, TLR-stimulation of dendritic 
cells (DC) can induce high IL-6 levels during cognate 
interaction, causing the responding T cells to produce 
more IL-2 [14]. In this current study, we examined the 
effects of IL-2 and IL-6 on the CD8+ T cell response to 
influenza virus and showed that the addition of these 
cytokines restored the response to influenza in aged mice 
to that observed in young mice. 
 To complement these murine experiments, we also 
examined age-related changes in the CD8+ cytolytic T cell 
response to influenza in human PBMC following influenza 
vaccination using methods previously developed in our 
laboratory [15]. To that end, we postulated that the addition 
of key cytokines in vitro could restore the cytolytic 
response of aged T cells to that seen in younger adults. 
Previously, we demonstrated that vaccinated older adults 
exhibited T cell populations with reduced proportions and 
numbers of memory cells [15]. In addition, the decline 
in naïve T cells relative to memory T cells was much 
more dramatic in the CD8+ compared to the CD4+ T cell 
compartment in older individuals. With aging, the effector 
T cell subset displayed diminished generation of cytolytic 
effector T cells, including a reduction in GrB+/Perforin+ 
(Perf+) cells and a decline in cytolytic function [15]. 
Furthermore, effector memory and effector CD8+ T-cell 
subsets obtained from older subjects exhibited diminished 
proliferative responses and cytolytic activity in response 
to influenza A/H3N2 challenge. These age-related declines 
in proliferative responses and cytolytic activity were much 
less marked in the corresponding CD4+ as compared to 
CD8+ T cell subsets [15]. We postulated that these results 
could be attributed to changes involving the CD8+ T cell 
subset, as these are driven to a late stage or terminally 
differentiated state where they lose cytolytic function [16, 
17]. Consistent with this hypothesis, GrB continues to be 
expressed in a large proportion of these CD8+ T cells but in 
the absence of Perf [7, 15, 18] and thus cannot contribute 
to cytolytic activity against influenza virus-infected cells.
In a pre-clinical model using human PBMC to test 
different adjuvants combined with split-virus influenza 
vaccines (SVV), we have shown that addition of toll-
like receptor (TLR) agonists can be used to improve 
the IFNγ:IL-10 ratios as well as GrB responses to 
influenza challenge [19]. The addition of a TLR4 agonist, 
Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-
SE), stimulated myeloid dendritic cells to produce 
inflammatory cytokines (i.e., TNFα, IL-1, IL-6). This 
effect was associated with a dramatic reduction in IL-10 
levels in response to influenza challenge when PBMC 
were pre-treated with TLR4/SVV compared to SVV 
alone [19]. The experiments reported herein analyze the 
mechanism for these observations. 
With the above considerations in mind, we sought 
to explore the hypothesis that enhanced levels of key 
cytokines would improve the response of aged human T 
cells to influenza virus challenge. As part of this effort, 
we tested recombinant IL-2, IL-6, IL-4, IL-10 and IL-
17A, selected on the basis of existing cytokine assay 
data, in order to evaluate the capacity of other potential 
key regulatory cytokines to reverse age-related declines 
in CD8+ T cells. We observed that PBMCs from older 
adults produce lower IL-2 levels and higher IL-6 levels 
following an influenza challenge when compared to those 
from younger individuals. Nevertheless, supplementation 
with a combination of IL-2 and IL-6 was most effective in 
reversing age-related defects in CD8+ T cell responses to 
influenza, thus offering important evidence supporting the 
clinical potential of selecting more effective adjuvants as 
part of an effort designed to improve the effectiveness of 
influenza vaccines in older people. 
results
Granzyme b expression by murine memory cd8+ 
t cells can be enhanced by the addition of Il-2 
and Il-6
GrB is an important effector molecule used in 
fighting viral infections and declines in expression could 
negatively impact viral clearance. In order to examine 
how aging affects the memory CD8+ T cell response to 
influenza infection and GrB expression, young and old 
mice were infected with a sublethal dose of influenza 
A/PR/8/34 (PR8), and splenocytes were analyzed one 
month later. Figure 1A shows that the percent and total 
number of CD8+ T cells in the spleens of these mice 
were not significantly different. In addition, the percent 
and number of NP-specific CD8+ T cells in the spleen 
was not significantly different between young and old 
groups. These splenocytes were then cultured for 7 days 
with influenza virus with or without added IL-2 and IL-6. 
These two cytokines were chosen based on their ability to 
enhance the function of memory CD4+ T cells from old 
mice [11]. On day 7, total CD8+ T cells were analyzed 
(Figure 1B). In both young and old groups, the addition 
of IL-2 and IL-6 to splenocyte cultures increased the total 
number and the percent of CD8+ T cells recovered and 
total number of GrB expressing CD8+ T cells. Importantly, 
the young group stimulated with virus alone expressed 
a higher percentage and number of GrB expressing 
cells compared to the old group, but this difference was 
overcome by the addition of the cytokines. 
A similar pattern was also observed for influenza-
specific CD8+ T cells. Influenza nucleoprotein (NP)-
specific CD8+ T cells were detected with a MHC Class I 
tetramer. In both young and old groups, the number of NP-
specific CD8+ T cells was increased in cultures containing 
added IL-2 and IL-6 (Figure 1C). While there were almost 
no GrB expressing NP-tetramer+ cells in both young and 
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old groups stimulated with virus alone, the addition of 
IL-2 and IL-6 significantly enhanced GrB expression, 
regardless of age. This increase in GrB expression in 
NP-tetramer+ cells is also shown in Figure 1D for each 
individual young and old animal. Thus, overall, the 
addition of IL-2 and IL-6 to murine memory CD8+ T cells 
can boost their GrB expression, which could aid in viral 
clearance during an infection. Our studies then went on to 
determine if a similar enhancement could also be observed 
in human CD8+ T cells. 
older human cd8+ effector memory t cells 
exhibit increased apoptosis and diminished 
proliferative capacity in response to influenza 
when compared to young
We have previously shown that CD8+ effector 
T-cell subsets isolated from older adults, which co-
express intracellular GrB with Perf (GrB+Perf+) or exhibit 
the CD127+CD25± phenotype, also demonstrate strong 
cytolytic activity in response to virus challenge at 4 weeks 
Figure 1: NP-specific memory CD8+ t cells in vitro response to influenza can be augmented by the addition of cytokines. 
Mice were infected 4 weeks prior with 500 EID
50
 PR8 (H1N1) influenza to generate a lasting immune response. A. Splenocytes were 
analyzed on the day of harvest (day 0) by flow cytometric analysis of cells from individual young (4 month) and aged (18 month) mice. 
Graphs show the percent and total number of CD8+ and NP-specific CD8+ T cells (NP TET+). B.-D. Splenocytes from individual mice were 
then cultured for 7 days with 50 EID
50 
PR8 (H1N1) with or without IL-2 and IL-6 (10ng/ml). B. Analysis of total CD8+ T cells after 7 days 
of culture for percentage and total numbers of CD8+ T cells expressing granzyme B (GrB). C. Analysis of total NP tetramer-specific CD8+ 
T cells for percent and total numbers of cells with GrB expression. D. Comparison of total number of GrB expressing cells after 7-day 
secondary response to PR8 virus with and without IL-2 and IL-6. Each symbol represents a single animal. *p < 0.05. n.s. = not significant.
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following influenza vaccination. However, the response 
tends to be short-lived, with a significant reduction in 
the frequency and influenza-specific cytolytic activity 
involving CD8+ T cells by 10 weeks post-vaccination 
[15]. Therefore, we now compare responses involving 
CD8+ T cells obtained from young and older individuals 
10-20 weeks post-vaccination and stimulated ex vivo 
with influenza. Most T cells found in PBMC at this time 
express an effector memory phenotype [15]. PBMC were 
isolated and stimulated with live influenza virus. After 
20 hours in culture, older compared to young adults 
showed a higher proportion of total effector memory 
CD8+ (CD45RA+CCR7-) T cells (Figure 2A) but a 
significant reduction in the subset expressing GrB and 
Perf effector molecules following virus challenge (Figure 
2B). This indicates that the generation of memory cells 
is not diminished with aging, but that their functional 
cytolytic capacity is likely impaired. We next analyzed 
this CD45RA+CCR7-GrB+Perf+CD8+ T cell subset, which 
represent the putative memory cytotoxic population, 
by Annexin V staining as an indicator of apoptosis. 
Approximately twice as many of the GrB+Perf+ effector 
memory CD8+ T cells from older subjects expressed 
Annexin V, indicating that more than half of this subset 
Figure 2: High apoptotic tendency and decline in proliferative capacity in effector memory cd8+ t cells responding 
to influenza virus in older compared to young controls. Human peripheral blood mononuclear cells (n = 6/group) obtained 10 
or 20 weeks post-vaccination were cultured for 20 hr in the presence of influenza A/H3N2 live virus. A. Graphs show a representative 
scatter plot and compiled results of the proportion of CD8+ T cells that are CD45RA+CCR7- following influenza challenge. B. Gating on 
CD8+CD45RA+CCR7- T cells, the proportion of cytolytic effectors in the boxes (GrB+Perf+) in the representative scatter plots and graphs of 
the compiled results are shown. C. Gating on CD8+CD45RA+CCR7-GrB+Perf+ T cells, the proportion undergoing apoptosis (Annexin V+) 
are shown in the representative scatter plots and graphs of compiled results. Error bars represent standard error of the mean. *p < 0.0001.
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was undergoing an early stage of apoptosis (Figure 2C). 
This suggests that with aging the memory CD8+ T cell 
population that has CTL potential becomes more prone 
to apoptosis, which is responsible in some part for the 
generation of fewer cytotoxic effectors.
Il-2 and Il-6 enhance the proliferative capacity 
of human older cd8+ t cells and its memory 
effector subsets in response to influenza virus
It has been shown that the addition of exogenous 
IL-2 can maintain effector T cell proliferation, block 
apoptosis, and when added to in vitro cultures, can largely 
overcome the age-related decline in naive CD4+ T-cell 
Figure 3: The restorative effect of recombinant cytokines on aged CD8+ t cells and the proliferative capacity of its 
effector memory subset in older adults. A. Human CD8+ T cells (n = 5/group) from healthy older adults (70-80 years old) were 
sorted and stimulated with influenza H3N2 virus for 7 days with or without cytokines, then total CD8+ T cell numbers were counted. B. 
Representative histogram of human CD8+ T cells from a healthy older adult were sorted and stimulated with influenza H3N2 live virus for 
3 days in the presence or absence of recombinant IL-2 (10 ng/mL) and/or IL-6 (15 ng/mL), cells were stained with CFSE at a concentration 
of 1μM, and then cultured in fresh medium containing cytokines for another 3 days before FACS analysis. C. Compiled data (n = 5/group) 
showing the mean fluorescence intensity (MFI) of the CFSE staining demonstrating that the highest level of proliferation (lowest MFI) 
occurs with the addition of both IL-2 and IL-6. Error bars represent standard error of the mean. *p < 0.0001. 
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expansion [10, 11]. We have also found in murine studies 
that IL-6 plays a key role in enhancing expansion and 
survival of older adult naive CD4+ T-cells [10, 14]. Based 
on our observation of a major decline in the production 
of IL-2 in aged human PBMC in response to influenza 
challenge (unpublished data) and in vitro studies in the 
mouse, we designed experiments to evaluate the effect 
of possible key cytokines including IL-2, IL-6, IL-4, IL-
10, and IL-17A, on the generation of cytotoxic effector 
CD8+ T cells in response to influenza virus. To eliminate 
the effects of other PBMC on the observed responses, 
enhance influenza virus antigen presentation, and target 
T cell proliferation and differentiation, we sorted CD14+ 
monocytes, and CD4+ and CD8+ T cells from older 
individuals and cultured them at a 2:2:1 ratio with live 
influenza virus for 7 days with or without the addition 
of IL-2, IL-4, IL-6, IL-10, or IL-17A. Only IL-2, IL-4, 
and IL-6 showed a significant effect on the number of 
aged CD8+ T cells, with IL-2 having the greatest effect 
on enhancing cell number on day 7 of culture (Figure 
3A); IL-4 was a weaker stimulus than IL-2 in terms 
total cell numbers, with no impact on the tendency of 
aged effector memory CD8+ T cells to undergo apoptosis 
when compared to control cultures with no cytokines 
added (data not shown). Similar effects of cytokine 
supplementation were observed in young CD8+ T cells 
(Supplemental Figure 1). The effect of IL-2 and IL-6 on 
proliferation of CD8+ memory T cells from older adults 
was also assessed by CFSE staining. Figure 3B shows 
representative histograms of CFSE staining and compiled 
results of Mean Fluorescence Intensity (MFI) are shown in 
Figure 3C. Addition of both IL-2 and IL-6 together during 
culture with influenza virus induces significantly enhanced 
proliferation of these CD8+ T cells from older subjects.
Il-2 and Il-6 enhance cd8+ effector memory 
T-cell cytotoxicity both by blocking apoptosis and 
increasing expansion
Given the ability of IL-2 and IL-6 to enhance 
proliferation of effector memory CD8+ T-cells in samples 
from older individuals, we investigated whether IL-2 and 
IL-6 could also improve CTL function in the older adult 
PBMC cultures by additional mechanisms. First, we tested 
the effects on the apoptosis of CD8+ effector memory T 
cells with a cytolytic phenotype, GrB+Perf+. We found 
that the addition IL-2 plus IL-6, resulted in a significant 
decline in the proportion of Annexin V+ cytolytic effector 
T cells (CD8+CD45RA+CCR7-GrB+Perf+ T cells) that 
Figure 4: the restorative effect of different combinations of recombinant Il-2 and/or Il-6 on the apoptotic tendency 
and cytotoxicity in older cd8+ effector memory T cells. Human peripheral blood mononuclear cells (PBMCs) from healthy young 
(HY) and older (HO) adults were stimulated with influenza H3N2 virus with or without cytokines (recombinant IL-2 [10 ng/ml], IL-6 [15 
ng/ml], IL-10 [10 ng/ml]). A. Gating on CD8+CD45RA+CCR7-GrB+Perf+ T cells after 20 hours in culture, Annexin V staining shows that 
the apoptotic tendency of the HO cytolytic T cells is diminished by the addition of IL-2 and IL-6; the combined effect of these two cytokines 
in older adults reduces the frequency of apoptotic cells to that found in HY (n = 6/group). B. For the cytotoxicity assays, HO PBMCs (n 
= 3/group) were stimulated with virus for 1 day (open triangles) or 5 days (filled triangles) in medium with or without cytokines and the 
cytolytic subset (CD8+CD45RA+CCR7- CD127+CD25- T-cells) was sorted for the LDH release assay as described in Methods. The highest 
level of cytotoxicity was achieved with the addition of IL-2 and IL-6. Error bars represent standard error of the mean. *p < 0.0001, **p < 
0.005. 
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were undergoing apoptosis (Figure 4A). IL-2 or IL-2 plus 
IL-6 had a greater effect than IL-6 alone, which was not 
statistically different from no added cytokines in this assay. 
Added IL-2 plus IL-6 or IL-2 alone significantly decreased 
the proportion of apoptotic cytolytic cells in older adult 
CD8+ T cells, such that the proportion of apoptotic cells 
observed was similar to that found in the young adult 
response in the absence of any added cytokines. Thus, the 
response of the apoptotic older effector memory CD8+ T 
cells was dramatically improved by the addition of IL2 
plus IL-6 so that it became similar to that of young cells. 
Next, we evaluated the effect of IL-2 and IL-6 on 
the cytolytic activity of CD8+ memory effector T cells. 
The addition of IL-2 or IL-6 to cultures of CD8+ T cells 
from older individuals significantly enhanced the cytolytic 
activity of 5-day effector CD8+CD45RA+CCR7- T-cells 
against influenza-infected targets, and the addition of 
IL-2 plus IL-6 showed significantly greater cytolytic 
function than either IL-2 or IL-6 alone, suggesting the 
presence of potentially interacting effects (Figure 4B). At 
the same time, IL-10, used as a control, had no effect on 
cytolytic function (Figure 4B). No changes in cytolytic 
activity were observed after only one day of culture. 
Thus IL-2, especially in combination with IL-6, enhanced 
proliferation, reduced death and enhanced the cytolytic 
activity generated from effector memory CD8+ T cells.
Figure 5: IL-2 and IL-6 induced proliferation of influenza-specific CD8+ t cells in HlA-A2+ donors. Human PBMCs from 
healthy young (n = 8) and healthy older (n = 9) HLA-A2+ donors were stimulated with influenza H3N2 virus with or without cytokines 
(IL-2 [10 ng/ml], IL-6 [15 ng/ml) for 7 days, then stained with CD3, CD8, and MHC Class I tetramer to identify influenza-specific T cells. 
A. Representative dot plots gated on CD3+CD8+ T cells showing the proportion of MHC Class I tetramer+ cells for each culture condition. 
B., C. Comparison of IL-2 and/or IL-6 induced enhancement of influenza-specific CD8+ T cells on Day 0 (black bars) and Day 7 in young 
(B, white bars) and older (C, gray bars) adults. Error bars represent standard error of the mean. *p < 0.0001, **p < 0.01, ***p < 0.05. D. 
Graphs showing an approximate 4-fold increase in MHC Class I tetramer+ CD8+ T cells in both young D. and older E. adults when cultured 
with the addition of IL-2 plus IL-6 compared to no cytokines. Each symbol represents a single subject from graphs B. and C..
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The decline of influenza-specific older CD8+ t 
cells from HlA-A2 donors can be recovered by 
adding Il-2 plus Il-6
In order to track the in vitro response of influenza-
specific CD8+ T cells from our young and old cohorts, we 
identified them with a MHC Class I tetramer containing the 
immunodominant influenza M1 epitope (GILGFVFTL). 
Figure 5A shows the flow cytometric analysis of tetramer-
positive CD8+ T cells from one subject and demonstrates 
that addition of IL-2 plus IL-6 enhances the percentage 
of tetramer positive cells. Results compiled from young 
(Figure 5B) and older (Figure 5C) subjects also show this 
effect of IL-2 plus IL-6 on influenza-specific cells after 
5 days of culture. Importantly, although the young adults 
have higher frequencies of M1 tetramer+ cells, there is 
approximately a 4 to 5-fold increase in the frequency of 
these cells in both young and older adults in response to 
influenza challenge with the addition of IL-2 plus IL-6 to 
the cultures. The change in in vitro expansion of tetramer-
specific CD8+ T cells with the addition of IL-2 plus IL-6 
when compared to culturing with the virus alone is also 
shown for individual young and older subjects (Figure 
5D). 
dIscussIon
The response of PBMC from older individuals to 
live influenza virus in vitro is significantly reduced when 
compared to the response from younger individuals, 
with a lower frequency of cells responding and with 
reduced cytotoxic activity. Here we report that addition of 
exogenous IL-2 and IL-6 to influenza challenged PBMC, 
enhances the expansion and survival of the aged CD8+ 
T cell recall response, leading to more effector CD8+ T 
cells with higher cytotoxic activity. It should be noted 
that our human PBMC model system includes sorted 
monocytes and CD4+ and CD8+ T cells so that results 
are not confounded by individual subject differences in 
the numbers of cells within these different cell subsets 
in the PBMC culture, while at the same time supporting 
the critical interactions between these subsets in the 
generation of the responses measured. 
Studies in vitro with murine naive CD4+ T cells have 
previously shown that TLR agonists acting on dendritic 
cells (DC) cause enhanced production of IL-6 that with 
other elements dramatically enhances the responses of old 
naïve CD4+ T cells interacting in a cognate fashion with 
those DC [14, 20]. The CD4+ T cells divide more, undergo 
less apoptosis and produce more IL-2 [14]. In addition, 
a cocktail of pro-inflammatory cytokines, IL-6, plus 
IL-1 and TNFα added to cultures or to mice containing 
old naïve CD4+ T cells, results in striking enhancement 
and importantly in increased help for B cells [12, 13]. 
Thus, IL-6 in addition to an early described role as a B 
cell growth factors, is well-established as a mediator 
of CD4 and CD8 T cells function and is important for 
keeping T cells alive as they respond [21, 22]. In the 
model used in the study presented here, responses are 
assessed following ex vivo influenza virus challenge of 
PBMC from recently immunized donors, so it is likely 
that the responding CD8+ T cells are recently generated 
memory T cells. Thus these results suggest that in older 
individuals, the population of influenza-specific memory 
T cells generated by vaccination, or re-called from earlier 
exposures, are defective, and that the combination of IL-2 
and IL-6 is able to act together to substantially enhance 
responses. The fact that following vaccination, IL-2 plus 
IL-6 can improve human CD8+ T cell responses that are 
impaired in older adults, suggests that this pathway for 
enhanced response is present in both mice and humans and 
that it can act both on the memory CD8+ cells generated 
by vaccination, as well as on naïve CD4+ T cells. We 
note that aged T cell responses are enhanced by IL-2 
and IL-6 (shown herein), and by TLR agonist activated 
DC in both young and old mice [14, 20]. Similarly, we 
have previously shown that pro-inflammatory cytokines 
enhance proliferation and IL-2 production by aged naive 
CD4+ T cells in an NFκB-dependent manner [12, 13]; we 
have shown this both in vitro and in vivo with the pro-
inflammatory cytokines used as an adjuvant. We suggest 
that IL-6 acts as a “third” signal during TCR stimulation 
of CD4+ T cells and provides co-stimulation signals 
leading to enhanced responses. Thus it seems aged T 
cells retain some of their ability to respond effectively 
under conditions that induce highly activated DC and 
pro-inflammatory cytokines, such as those that occur with 
live replicating pathogens, but that their response to less 
“dangerous” challenges, such as isolated foreign proteins 
or inactivated vaccines is impaired. One can speculate that 
this shift may to some extent actually be advantageous 
since it could limit potential for the development of over-
exuberant responses to non-pathogens or self antigens.
It has been proposed that enhanced inflammatory 
responses to viral infections could be protective in terms 
of host defense, while at the same time “inflammaging”, 
overproduction of inflammatory molecules such as IL-6 
with aging, has been linked to an increased risk of age-
related frailty, morbidity and disability. In contrast, 
anti-inflammatory responses involving IL-10 and 
other mediators could potentially weaken resistance to 
infection, while contributing to healthy aging [23]. In 
determining the relevance of the above paradigm to our 
findings, we found that among the cytokines measured 
in our panel, the release of IL-1β, IL-6, MIP-1α and 
GM-CSF in ex vivo influenza-challenged PBMC was 
significantly increased in older compared to young adults. 
We observed that while production of both IFNγ and IL-
10 in whole PBMCs declined with age, the IFNγ:IL-10 
ratio declined, suggesting a possible shift toward a more 
anti-inflammatory response to influenza. Our previous 
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experiments showed that this decline is independent 
of age cohort and history of childhood exposure to 
different subtypes of influenza A [9], suggesting that 
the dysregulation of cytokine production is an intrinsic 
alteration in immune function that could be targeted in 
the development of immunotherapies including vaccines. 
One way to reconcile these divergent considerations is to 
suggest that the constitutive systemic production of pro-
inflammatory cytokines may desensitize T cell responses 
and lead to other negative consequences of inflammation, 
while increases in targeted pro-inflammatory cytokines 
produced by antigen-presenting cells in response to 
infection, that interact with responding T cells, may 
strikingly enhance the response of those cells (Reviewed 
in [24]).
It has been previously shown that both dendritic cell 
(DC) and CD28 costimulation are required for maintenance 
of the effector phase of influenza-specific CD8+ T cell 
responses in vivo [25]. IL-2 treatment has been shown in 
the mouse to restore the effector phase of the response to 
influenza in the absence of CD28 costimulation [26]. In 
humans, the loss of CD28 expression on CD8+ T cells in 
association with the late stage or terminal differentiation 
of these memory T cells would predict a defective effector 
phase and early apoptosis of the effector CD8+ T cells 
responding to influenza challenge. Our results confirm 
this prediction showing that reduced cytolytic activity in 
older compared to young adults is associated with higher 
frequencies of effector CD8+ T cells undergoing apoptosis 
and a decline in the proliferative response to the virus. 
Furthermore, we show that IL-2 supplementation could 
reduce the rate of apoptosis in effector CD8+ T cells 
and improve the proliferative response to the virus, and 
when combined with IL-6, may restore these responses 
to those demonstrated in young adults. While the increase 
in effector CD8+ T cells expressing the IL-2 receptor 
(CD25) was associated with a decline in the proportion of 
CD25+ T cells with a naïve phenotype, it is likely that this 
naïve subset represents the previously identified subset of 
CD8+CD45R0+CD25+ T cells which efficiently expand and 
differentiate into functional effector T cells upon antigenic 
challenge [27]. 
Our previous studies have documented a defect 
in the frequency and cytolytic activity of CD8+ T cells 
responding to a live influenza virus challenge following 
vaccination in older compared to young adults. Further, 
the duration of the response to influenza vaccination is 
more short-lived in older adults. In this study, we showed 
that this decline in the frequency and cytolytic function 
of effector CD8+ T cells (GrB+Perf+) is associated with 
increased apoptosis in the responding cells in older 
compared to young adults. Proliferation assays confirmed 
that this was associated with a loss of effector CD8+ T 
cells in the older adult PBMC. An earlier report found 
a similar increase in apoptosis during the response of 
naïve CD4+ T cells from old mice [14, 28], suggesting a 
shift in susceptibility to cell death during response may 
be a general characteristic of aged T cells. The sharing 
of this set of pathways for enhancing T cell responses 
between mice and humans, between CD4+ and CD8+ T 
cells and between naïve cells studied in mice and memory 
cells studied here suggests this is a well-conserved and 
functionally important, general pathway in T cells. 
While it has been previously shown that both 
IL-2 and IL-6 can reverse age-related changes in T cell 
proliferation and function [10, 13, 29], we found that 
the combined effect of these two cytokines improved 
the proliferative response to live influenza challenge, 
with an associated reduction in the proportion of old 
effector T cells undergoing apoptosis. The addition of 
IL-6 resulted in a small increase in the differentiation of 
effector memory T cells relative to the effect of IL-2 but 
there appeared to be interacting effects between the two 
cytokines that resulted in most of the effector memory 
CD8+ T cells becoming effector T cells over the 5-7 days 
of culture. 
We have previously shown that a TLR4 agonist, 
GLA, when added to a split influenza virus vaccine, 
improved the CD8+ T cell response of older individuals 
[19] in association with enhanced IL-6 production by 
myeloid DC in the cultures. Our previous results with 
this TLR4 agonist would suggest that adjuvants could 
be added to influenza proteins or split-virus vaccines 
to stimulate key cytokines including IL-2 and IL-6 and 
activate cytokine signal transduction pathways to enhance 
the proliferation and differentiation potential of memory 
and effector T cells in older adults. 
In conclusion, the ability of IL-2 and IL-6 
supplementation to restore the response of influenza-
specific memory CD8+ T cells to become functional 
effectors in older adults, to levels close to those observed 
in young adults in response to influenza challenge, 
provides a mechanism that could be targeted in the design 
of new influenza vaccines. Most importantly, these results 
raise the possibility of adding adjuvants to currently 
approved influenza vaccines to improve vaccine efficacy 
in the older population most vulnerable to the serious 
complications of influenza. 
mAterIAls And metHods
ethics statement
This study was performed under strict accordance 
with the recommendations from the Guide for the Care 
and Use of Laboratory Animals. All animals were cared 
for according to local, state, and federal regulation in 
accordance with protocol approved by the University of 
Connecticut Health Center Institutional Animal Care and 
Use Committee (A3471) and consistent with National 
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Institutes of Health guidelines for the care and use of 
animals.
All human subjects were recruited following written 
informed consent. The Institutional Review Board of the 
University of Connecticut Health Center approved all 
protocol and informed consent documents.
mice
Young (4 months) C57BL/6J male mice were 
purchased from the Jackson Laboratory and aged (18 
months) C57BL/6 male mice were obtained from the 
National Institute on Aging colony.
Virus
Mice were anesthetized with Isofluorane (4% 2.0L/
min) and infected with A/PR/8/34 (PR8), intranasally at 
500 EID
50
 in 50 uL PBS. Mice were monitored daily for 
weight loss for 21 days and removed from the study if 
weight loss exceeded 30%. 
culturing murine splenocytes
Single cell suspensions of splenocytes were 
generated by passing individual spleens through a 70 um 
filter and lysing red blood cells with 1.0ml ACK (Gibco) 
for 1 minute. Splenocytes were cultured at 106 cells/ml 
and stimulated with 50EID
50
 PR8 influenza for 7 days. 
Half of these cultures were supplemented with 10ng/ml 
interleukin 2 and 10ng/ml interleukin 6 (R & D Systems). 
Flow cytometry of murine splenocytes
Freshly harvested splenocytes and cells cultured for 
7 days were stained with anti-CD3ε PerCP/Cy5.5 (Clone: 
145-2C11, BioLegend), anti-CD-8 PE-Cy7 (Clone: 53-6.7, 
eBioscience) and anti-GranzymeB AlexaFluor700 (Clone: 
GB11, BD Biosciences). A MHC class I peptide tetramer 
specific for influenza virus NP
366-374
/Db conjugated to PE 
was obtained from the Molecular Biology Core Facility 
at Trudeau Institute (Saranac Lake, NY). Splenocytes and 
day 7 effectors were incubated on ice for 60 minutes with 
the Class I tetramer prior to staining with surface antigens 
on ice for 30 minutes. Cells were permeabilized according 
to the BD Cytofix/Cytoperm protocol and subsequently 
stained for intracellular proteins. Data were acquired on 
the BD LSR II flow cytometer and analyzed using FlowJo 
9.3.3 software.
Human subjects
Twenty-four healthy young (20-30 years old) and 
twenty-three older adults (≥65 years old) from the Greater 
Hartford Area, CT, USA, were studied at 10-weeks or 
20-weeks post-vaccination in the winter of 2011-2012 and 
2014-2015. For both age groups, subjects were excluded 
for any acute respiratory illness presenting in the 2 weeks 
prior to study enrolment, insulin-requiring diabetes, 
advanced heart failure or lung disease, any condition or 
medication causing immunosuppression (i.e., prednisone 
> 10mg/day), or any contraindications to influenza 
vaccination.
cell culture and virus stimulation
Human PBMC were isolated from venous blood 
samples by Histopaque gradient purification and 
stimulated in 0.5 ml of AIM V media (Gibco) containing 
1.0x106 PBMC and 4x106 TCID
50
 of influenza A/
Victoria/3/75 (H3N2) virus for 20 hours as previously 
described [15]. For cytotoxicity assays, cells were 
activated with Dynabeads Human T-Activator CD3/CD28 
(Invitrogen) for 6 hr, the Dynabeads removed, and then 
the cells were stimulated with live influenza virus for 
5 days in AIM V medium containing 10% Human AB 
serum (Sigma). For cell surface and MHC-Class I tetramer 
staining, CD14+ monocytes and CD4+ and CD8+ T cells 
were sorted and mixed at a 2:2:1 ratio and stimulated 
with live influenza virus for 7 days before staining with 
tetramers and antibodies to other T cell surface markers. 
Recombinant cytokines were added at concentrations of 
10 ng/ml for IL-2, IL-4, IL-10 and IL-17A, and at 15 ng/
ml for IL-6 (R&D). 
Flow cytometry and antibodies
To determine the phenotype of T cells responding 
to influenza challenge, PBMCs were prepared and stained 
as previously described [15]. Briefly, the cells were 
washed with cold 0.2% FBS/PBS twice before adding the 
following conjugated monoclonal antibodies: Human anti-
CD8-FITC (OKT8), anti-CD25-APC-Cy7 (eBioscience), 
anti-CD127-Biotin/PE-Texas Red, anti-CCR7 PE-Cy7 
(3D12) and anti-CD8-APC-Cy7 (SK1) (BD Bioscience), 
, anti-CD45RA-eFluor 450 (HI100) and anti-CD4-
Alexa Fluor 700 (OKT4) (eBioscience). For intracellular 
staining, cells were fixed with 2% paraformaldehyde and 
permeabilized with permeabilization buffer (eBioscience), 
then incubated with anti-GrB Alex Fluor 647 (GB11) 
and anti-Perforin PE (δG9), or human anti-IL-2-FITC 
(MQ1-17H12), anti-IL-4-PE (MP4-25D2), anti-IL-
6-V450 (MQ2-13A5), anti-TNF-α-PE-Cy7 (MAb11) 
(BD Bioscience) anti-IFN-γ-PerCP-Cy5.5 (4S.B3) 
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(eBioscience) or anti-Stat3 (pS727)-Alexa Fluor 488 
(49/p-Stat3) and anti-Stat5 (pY694)-Alexa Fluor 647 
(47/Stat5) (BD Bioscience) antibodies. For intracellular 
cytokine staining, Brefeldin A solution (eBioscience) was 
added 5 hours before staining. For Annexin V staining, 
cells were cultured with serum free medium for 4 hours, 
then washed with binding buffer and incubated with 
fluorochrome-conjugated Annexin V (eBioscience). For 
CFSE staining, CD8+ T cells were stimulated with virus 
for 3 days with or without cytokines, CFSE (eBioscience) 
was added into cell culture at the concentration of 1 μM 
for 10 min at room temperature, and then the cells were 
washed and cultured in fresh medium for another 3 days. 
For influenza-specific MHC Class I Tetramer Staining 
in HLA-A2 Donors, human PBMC were prepared and 
stimulated with influenza A/Victoria/3/75 (H3N2) virus for 
7 days in 0.2 ml of AIM V media containing 5x105 PBMC 
in a 96 well flat-bottom plate. The MHC Class I human 
Tetramer-Streptavidin-Allophycocyanin (iTAgTM MHC 
Class I human Tetramer-SA-APC, MBL International 
Corporation, Woburn, MA) which is used for HLA-A2+ 
donors and is specific for influenza M1 (GILGFVFTL). 
Cells were stained with surface markers and tetramer for 
one hour at room temperature. For cell sorting, human 
PBMC were prepared as above and sorted by using FACS 
Vantage SE/DIVA High Speed Sorter (BD Biosciences) 
running DIVA 5.0 Software. Data were acquired on the 
BD LSR II flow cytometer and analyzed using FlowJo 
9.3.3 software.
cytotoxicity assay
Human PBMCs were prepared and cultured in AIM 
V medium containing 10% human AB serum (Sigma) 
with influenza A/Victoria/3/75 stimulation for 5-6 days. 
CD8+ T cells were sorted into different effector subsets 
defined by antibody staining before they were added 
to the cytotoxicity assay. Anti-CD3/CD28 activated 
autologous lymphoblast target cells were infected with 
influenza H3N2 virus for 30 min and added into V-bottom 
96-well plate at a dilution of 104 cells/100 µl per well in 
triplicate before adding sorted effector T cell subsets at 
E/T (effector/target) ratios of 5:1 and 3:1; co-cultures were 
incubated for 4hr at 37°C [15]. Lactate dehydrogenase 
(LDH) activity released in the cell free supernatants was 
determined using the CytoTox 96® Non-Radioactive 
Cytotoxicity Assay (Promega).
statistical analysis
Unpaired t-tests were used to compare the two age 
groups for cytokine levels, GrB activity, and frequencies 
in the different CD8+ T-cell subsets. Analysis within age 
groups was done by the paired Student’s t test. Analysis 
of variance (ANOVA) was used for comparisons across 
different culture conditions and adjusted using the Tukey 
HSD for multiple comparisons. Non-parametric tests 
were used where the data was not normally distributed. 
Analyses were performed using Origin Pro 8.5 (OriginLab, 
MA) and SPSS 16.0 (Chicago, IL). P values < 0.05 were 
considered statistically significant.
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